Abstract
For the development of new antiepileptics the kainate receptors, GluR6 and GluR5, are important targets. Based on the anticonvulsant effects of chinazolines and thieno[2,3-d]pyrimidines that are known from the literature, thieno[2,3-d][1.3]oxazines were synthesized and studied for their inhibitory properties at GluR6 and GluR5 receptors. The strongest inhibitor activity was observed with 5-methyl-6-phenyl-thieno[2,3-d][1.3]oxazines with C1 or C3-substituents in position 2 (3b-f). The 2-trihalide-methyl-substituted compounds 3c and 3d were the most active inhibitors at the GluR5- receptor (IC50=23.4 μmol, 16 μl). The 2-isopropyl-substituted compound 3f displayed the strongest activity at the GluR6- receptor (IC50=8.7 μmol). A number of thieno[2,3-d][1.3]thiazines and thieno[2,3-d]pyrimidines that were synthesized from the thieno[2,3][1.3]oxazines did not show any activity.
Keywords: Glutamate receptor antagonists, kainate receptor antagonists, anticonvulsives, thieno[2,3-d][1.3]oxazines, thieno[2,3-d][1.3]thiazines, thieno[2,3-d]-pyrimidines
Current Medicinal Chemistry
Title: Synthesis of Thieno[2,3-d]oxazines and Thieno[2,3-d]thiazines as Subtype Specific Kainate Receptor Antagonists
Volume: 16 Issue: 35
Author(s): D. Briel, A. Rybak, S. Mann, C. Kronbach and K. Unverferth
Affiliation:
Keywords: Glutamate receptor antagonists, kainate receptor antagonists, anticonvulsives, thieno[2,3-d][1.3]oxazines, thieno[2,3-d][1.3]thiazines, thieno[2,3-d]-pyrimidines
Abstract: For the development of new antiepileptics the kainate receptors, GluR6 and GluR5, are important targets. Based on the anticonvulsant effects of chinazolines and thieno[2,3-d]pyrimidines that are known from the literature, thieno[2,3-d][1.3]oxazines were synthesized and studied for their inhibitory properties at GluR6 and GluR5 receptors. The strongest inhibitor activity was observed with 5-methyl-6-phenyl-thieno[2,3-d][1.3]oxazines with C1 or C3-substituents in position 2 (3b-f). The 2-trihalide-methyl-substituted compounds 3c and 3d were the most active inhibitors at the GluR5- receptor (IC50=23.4 μmol, 16 μl). The 2-isopropyl-substituted compound 3f displayed the strongest activity at the GluR6- receptor (IC50=8.7 μmol). A number of thieno[2,3-d][1.3]thiazines and thieno[2,3-d]pyrimidines that were synthesized from the thieno[2,3][1.3]oxazines did not show any activity.
Export Options
About this article
Cite this article as:
Briel D., Rybak A., Mann S., Kronbach C. and Unverferth K., Synthesis of Thieno[2,3-d]oxazines and Thieno[2,3-d]thiazines as Subtype Specific Kainate Receptor Antagonists, Current Medicinal Chemistry 2009; 16 (35) . https://dx.doi.org/10.2174/092986709789878283
DOI https://dx.doi.org/10.2174/092986709789878283 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Are Selenoproteins Important for the Cancer Protective Effects of Selenium?
Current Nutrition & Food Science In Vivo Experimental Models of Epilepsy
Central Nervous System Agents in Medicinal Chemistry The Role of Blood-Brain Barrier Studies in the Pharmaceutical Industry
Current Drug Metabolism Release of Adenosine and ATP During Ischemia and Epilepsy
Current Neuropharmacology The Multiple Aspects of Stroke and Stem Cell Therapy
Current Molecular Medicine Long-Term Effects of Hypoxia-Reoxygenation on Thioredoxins in Rat Central Nervous System
Current Pharmaceutical Design QSAR Studies for the Pharmacological Inhibition of Glycogen Synthase Kinase-3
Medicinal Chemistry Cortical Auditory Dysfunction in Childhood Epilepsy: Electrophysiologic Evidence
Current Pediatric Reviews Reverse Iontophoretic Extraction of Gabapentin: A Mechanistic Study
Current Drug Delivery The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Editorial [Hot topic:VIP and PACAP: Novel Approaches to Brain Functions and Neuroprotection (Executive Guest Editors: Seiji Shioda and Illana Gozes)]
Current Pharmaceutical Design GABA Puts a Stop to Pain
Current Drug Targets - CNS & Neurological Disorders Preface
Current Pharmaceutical Design A Timely Review of State-of-the-Art Chronopharmaceuticals Synchronized with Biological Rhythms
Current Drug Delivery Medicinal Applications of Cannabinoids Extracted from Cannabis sativa (L.): A New Route in the Fight Against COVID-19?
Current Pharmaceutical Design Adult Neurogenesis and the Diseased Brain
Current Medicinal Chemistry Calixarene: A Versatile Material for Drug Design and Applications
Current Pharmaceutical Design Neurogenic Drugs and Compounds
Recent Patents on CNS Drug Discovery (Discontinued) Estrogen and Serotonin: Complexity of Interactions and Implications for Epileptic Seizures and Epileptogenesis
Current Neuropharmacology Electroencephalography and Dementia: A Literature Review and Future Perspectives
CNS & Neurological Disorders - Drug Targets